Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACTU Actuate Therapeutics	$9.78 +5.2%	$7.87	$5.51 ▼ $11.73	$191.02M	N/A	47,698 shs	93,384 shs
IPSC Century Therapeutics	$0.52 -0.3%	$0.53	$0.34 ▼ $3.47	$44.80M	1.8	448,684 shs	414,777 shs
VYGR Voyager Therapeutics	$3.44 +4.7%	$3.53	$2.75 ▼ $9.55	$190M	0.95	443,932 shs	234,577 shs
YMAB Y-mAbs Therapeutics	$4.05 +4.4%	$4.59	$3.76 ▼ $16.11	$175.68M	0.53	319,561 shs	109,422 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACTU Actuate Therapeutics	+0.98%	+1.09%	+36.36%	+5.44%	+929,999,900.00%
IPSC Century Therapeutics	-1.51%	-3.43%	+26.91%	-31.45%	-84.48%
VYGR Voyager Therapeutics	+0.92%	-7.87%	+7.19%	-41.43%	-62.60%
YMAB Y-mAbs Therapeutics	+0.52%	-8.71%	-9.35%	-37.12%	-77.45%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IPSC Century Therapeutics	1.6614 of 5 stars	3.5	1.0	0.0	0.0	1.4	1.7	0.6
VYGR Voyager Therapeutics	4.5454 of 5 stars	4.6	1.0	0.0	4.6	1.6	1.7	1.9
YMAB Y-mAbs Therapeutics	3.9427 of 5 stars	4.4	3.0	0.0	0.0	3.3	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACTU Actuate Therapeutics	3.00	Buy	$20.50	109.61% Upside
IPSC Century Therapeutics	3.00	Buy	$4.40	746.15% Upside
VYGR Voyager Therapeutics	3.11	Buy	$13.97	306.59% Upside
YMAB Y-mAbs Therapeutics	2.82	Moderate Buy	$17.40	329.63% Upside

Current Analyst Ratings Breakdown

Latest IPSC, ACTU, VYGR, and YMAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/22/2025	ACTU Actuate Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00
4/22/2025	YMAB Y-mAbs Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Underperform	$3.00
4/8/2025	VYGR Voyager Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
4/3/2025	IPSC Century Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $2.00
3/28/2025	IPSC Century Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/24/2025	IPSC Century Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $7.00
3/21/2025	IPSC Century Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $5.00
3/21/2025	YMAB Y-mAbs Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $12.00
3/20/2025	IPSC Century Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$4.00 ➝ $2.00
3/17/2025	ACTU Actuate Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$20.00
3/13/2025	VYGR Voyager Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $12.00

(Data available from 5/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
IPSC Century Therapeutics	$6.59M	6.80	N/A	N/A	$3.06 per share	0.17
VYGR Voyager Therapeutics	$80.00M	2.37	$2.44 per share	1.41	$5.37 per share	0.64
YMAB Y-mAbs Therapeutics	$87.69M	2.09	N/A	N/A	$2.32 per share	1.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACTU Actuate Therapeutics	-$24.75M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
IPSC Century Therapeutics	-$136.67M	-$1.63	N/A	N/A	N/A	-4,837.73%	-61.66%	-31.78%	5/8/2025 (Estimated)
VYGR Voyager Therapeutics	$132.33M	-$1.46	4.84	N/A	N/A	15.80%	8.33%	6.15%	5/12/2025 (Estimated)
YMAB Y-mAbs Therapeutics	-$21.43M	-$0.67	N/A	N/A	N/A	-28.22%	-24.61%	-18.49%	5/13/2025 (Estimated)

Latest IPSC, ACTU, VYGR, and YMAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	YMAB Y-mAbs Therapeutics	-$0.21	N/A	N/A	N/A	$19.97 million	N/A
5/8/2025	Q1 2025	IPSC Century Therapeutics	-$0.31	N/A	N/A	N/A	N/A	N/A
5/6/2025	Q1 2025	VYGR Voyager Therapeutics	-$0.35	-$0.53	-$0.18	-$0.53	$13.55 million	$6.47 million
3/19/2025	Q4 2024	IPSC Century Therapeutics	-$0.45	-$0.43	+$0.02	-$0.43	$0.67 million	$4.18 million
3/11/2025	Q4 2024	VYGR Voyager Therapeutics	-$0.35	-$0.59	-$0.24	-$0.59	$16.58 million	$4.39 million
3/4/2025	Q4 2024	YMAB Y-mAbs Therapeutics	-$0.13	-$0.15	-$0.02	-$0.15	$26.70 million	$26.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	N/A
IPSC Century Therapeutics	N/A	N/A	N/A	N/A	N/A
VYGR Voyager Therapeutics	N/A	N/A	N/A	N/A	N/A
YMAB Y-mAbs Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACTU Actuate Therapeutics	N/A	1.68	1.68
IPSC Century Therapeutics	N/A	10.39	10.39
VYGR Voyager Therapeutics	N/A	8.45	8.45
YMAB Y-mAbs Therapeutics	N/A	3.92	3.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACTU Actuate Therapeutics	N/A
IPSC Century Therapeutics	50.20%
VYGR Voyager Therapeutics	48.03%
YMAB Y-mAbs Therapeutics	70.85%

Insider Ownership

Company	Insider Ownership
ACTU Actuate Therapeutics	69.34%
IPSC Century Therapeutics	6.80%
VYGR Voyager Therapeutics	6.39%
YMAB Y-mAbs Therapeutics	22.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACTU Actuate Therapeutics	10	19.53 million	N/A	N/A
IPSC Century Therapeutics	170	86.16 million	79.25 million	Optionable
VYGR Voyager Therapeutics	100	55.31 million	52.15 million	Optionable
YMAB Y-mAbs Therapeutics	150	45.28 million	34.71 million	Optionable

IPSC, ACTU, VYGR, and YMAB Headlines

Recent News About These Companies

Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)

May 7 at 7:05 AM | globenewswire.com

Why Y-mAbs Therapeutics, Inc.’s (YMAB) Stock Is Down 5.65%

May 6 at 7:49 PM | aaii.com

Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025

May 6 at 7:15 AM | globenewswire.com

Short Interest in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Drops By 16.1%

May 5 at 4:56 AM | marketbeat.com

2,861,825 Shares in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Acquired by Acorn Capital Advisors LLC

May 4, 2025 | marketbeat.com

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Short Interest Down 16.1% in April

May 4, 2025 | americanbankingnews.com

Caligan Partners LP Has $13.84 Million Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

May 3, 2025 | marketbeat.com

Renaissance Technologies LLC Raises Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

May 3, 2025 | marketbeat.com

Y-mAbs Therapeutics (YMAB) Projected to Post Earnings on Tuesday

May 1, 2025 | marketbeat.com

JPMorgan Chase & Co. Raises Stock Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

April 30, 2025 | marketbeat.com

Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline

April 29, 2025 | zacks.com

Boothbay Fund Management LLC Buys 136,264 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

April 29, 2025 | marketbeat.com

Y-mAbs Therapeutics announces presentation of PK data of CD38-SADA

April 28, 2025 | markets.businessinsider.com

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) latest 13% decline adds to one-year losses, institutional investors may consider drastic measures

April 27, 2025 | finance.yahoo.com

Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting

April 27, 2025 | globenewswire.com

Brookline Capital Management Weighs in on YMAB Q1 Earnings

April 27, 2025 | marketbeat.com

Y-mAbs announces first patient dosed in Phase 1 trial of CD38-SADA PRIT platform

April 26, 2025 | markets.businessinsider.com

Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma

April 25, 2025 | globenewswire.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Downgraded to "Underperform" Rating by Bank of America

April 24, 2025 | marketbeat.com

Y-mAbs Therapeutics downgraded to Underperform from Neutral at BofA

April 23, 2025 | markets.businessinsider.com

Y-mAbs downgraded to Underperform at BofA on tough near-term setup

April 23, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Are Tariffs Threatening Disney’s Comeback Story?
By Jea Yu | April 9, 2025
View Are Tariffs Threatening Disney’s Comeback Story?
Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
By Jeffrey Neal Johnson | April 25, 2025
View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
By Nathan Reiff | April 30, 2025
View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
3 Robotics Stocks That Could Benefit From U.S. Manufacturing Boom
By Nathan Reiff | April 10, 2025
View 3 Robotics Stocks That Could Benefit From U.S. Manufacturing Boom
Rockwell Automation: Tailwinds From Onshoring U.S. Production
By Thomas Hughes | May 8, 2025
View Rockwell Automation: Tailwinds From Onshoring U.S. Production

IPSC, ACTU, VYGR, and YMAB Company Descriptions

Actuate Therapeutics NASDAQ:ACTU

$9.78 +0.48 (+5.16%)

Closing price 03:58 PM Eastern

Extended Trading

$9.90 +0.12 (+1.23%)

As of 06:13 PM Eastern

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Century Therapeutics NASDAQ:IPSC

$0.52 0.00 (-0.34%)

Closing price 04:00 PM Eastern

Extended Trading

$0.52 0.00 (0.00%)

As of 05:52 PM Eastern

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Voyager Therapeutics NASDAQ:VYGR

$3.44 +0.16 (+4.73%)

Closing price 03:59 PM Eastern

Extended Trading

$3.36 -0.07 (-2.15%)

As of 06:35 PM Eastern

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Y-mAbs Therapeutics NASDAQ:YMAB

$4.05 +0.17 (+4.38%)

Closing price 03:59 PM Eastern

Extended Trading

$4.04 -0.01 (-0.37%)

As of 05:29 PM Eastern

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time